ArticleFrontiers in oncology2026
AI models based on gadoxetic acid-enhanced MRI to predict treatment response and prognosis after TACE in hepatocellular carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To develop and validate radiomics and deep learning models based on the hepatobiliary phase (HBP) of gadoxetic acid-enhanced MRI (EOB-MRI) for the noninvasive prediction of treatment response and prognosis following transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC). Materials and methods: From April 2018 to September 2024, 160 patients with Barcelona Clinic Liver Cancer (BCLC) stage A or B HCC (>3 cm) were retrospectively enrolled and randomly divided into training (n = 112) and test (n = 48) sets. An independent cohort of 38 HCC patients was used for external validation. Twenty-six radiomic features were extracted using LASSO to construct a machine learning model using eXtreme gradient boosting (XGBoost). A deep convolutional neural network (DCNN) based on the ResNet50 architecture was used to develop a deep learning model. A clinical model was built via multivariate logistic regression. Model performance was evaluated by the area under the curve (AUC), calibration curves, and decision curve analysis (DCA). Kaplan-Meier analysis of combined deep learning and radiomics(DLR) scores was used to estimate overall survival in the follow-up cohort (n = 117). Results: BCLC stage (P = 0.035), tumor number (P = 0.015), and tumor size (P = 0.013) were independent clinical predictors. In the training set, the AUCs (95% CI) for the clinical, radiomics (XGBoost), and deep learning (DCNN) models were 0.79, 0.84, and 0.96, respectively. In the test set, the AUCs were 0.70, 0.80, and 0.92, respectively. In the external validation set, the AUCs were 0.77, 0.80, and 0.86, respectively. The DCNN model showed superior calibration and the highest net clinical benefit in DCA. In addition, multivariable Cox regression revealed that DLR model output was an independent risk factor for the overall survival (hazard ratio: 15.9, 95% CI: 4.49-56.33; p < 0.001). Conclusion: HBP-based AI models effectively predicted TACE response and prognosis in HCC patients, with the DCNN model showing the best performance. The integrated DLR model demonstrated high predictive accuracy and may serve as a reliable tool for individualized treatment planning in precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.